Department of Clinical Psychology and Psychological Therapies, University of East Anglia, United Kingdom.
Lancashire & South Cumbria NHS Foundation Trust, Preston, United Kingdom; University of Liverpool, Liverpool, United Kingdom.
J Anxiety Disord. 2024 Aug;106:102913. doi: 10.1016/j.janxdis.2024.102913. Epub 2024 Jul 29.
Concerns regarding retraumatisation have been identified as a barrier to delivering trauma-focused therapy for post-traumatic stress disorder (PTSD). We explored clinicians' understanding of what constitutes potential signs of retraumatisation (PSoR), reported incidences of witnessing retraumatisation, use of (and confidence in) therapies for PTSD, fear of retraumatisation during therapy for PTSD, and whether having witnessed retraumatisation was associated with these variables. We surveyed 348 clinicians. There was variation in what clinicians viewed as PSoR. Retraumatisation was reported by clinicians in 3.4 % of patients undergoing trauma-focused therapy for PTSD. A variety of trauma-focused and non-trauma-focused therapies were routinely used, yet 14.4 % reported not using trauma-focused therapy. There was a significant negative correlation between participants' highest reported confidence in trauma-focused therapy and endorsement of PSoR (r = -.25) and fear of retraumatisation (r = -.28). Mean fear of retraumatisation was 30.3 (SD=23.4; a score we derived from asking participants out of 100 how much they worry about trauma-focused therapy being harmful in its own right/leading to a worsening of PTSD symptoms). Participants who had witnessed retraumatisation reported significantly greater endorsement of PSoR (d=.69 [95 % CI .37, 1.02]) and fear of retraumatisation (d=.94 [95 % CI .61, 1.26]). Confidence in using therapies for PTSD was varied and related to how clinicians understood retraumatisation. Retraumatisation is uncommon, but there is variability in clinicians' interpretation of what retraumatisation is, and its utility warrants research.
人们对再创伤的担忧已被认为是提供创伤聚焦疗法治疗创伤后应激障碍(PTSD)的障碍。我们探讨了临床医生对潜在再创伤迹象(PSoR)的理解,报告了目睹再创伤的发生率,使用(和对 PTSD 治疗的信心)治疗 PTSD 的疗法,对 PTSD 治疗中再创伤的恐惧,以及目睹再创伤是否与这些变量有关。我们调查了 348 名临床医生。临床医生对 PSoR 的看法存在差异。在接受创伤聚焦疗法治疗 PTSD 的患者中,有 3.4%的患者报告出现再创伤。各种创伤聚焦和非创伤聚焦疗法都在常规使用,但 14.4%的人报告未使用创伤聚焦疗法。参与者报告的对创伤聚焦疗法的最高信心与对 PSoR(r=-.25)和对再创伤的恐惧(r=-.28)的认可呈显著负相关。对再创伤的恐惧平均为 30.3(SD=23.4;这是我们从参与者中询问 100 分中他们对创伤聚焦疗法本身的担忧/导致 PTSD 症状恶化的程度得出的分数)。目睹过再创伤的参与者报告说,他们对 PSoR 的认可(d=.69 [95%CI.37, 1.02])和对再创伤的恐惧(d=.94 [95%CI.61, 1.26])显著更高。对 PTSD 治疗方法的信心各不相同,这与临床医生对再创伤的理解有关。再创伤并不常见,但临床医生对再创伤的解释存在差异,其效用值得研究。